Comparative Safety of Bioabsorbable Polymer Everolimus-Eluting, Durable Polymer Everolimus-Eluting, and Durable Polymer Zotarolimus-Eluting Stents in Contemporary Clinical Practice

Circ Cardiovasc Interv. 2021 Mar;14(3):e009850. doi: 10.1161/CIRCINTERVENTIONS.120.009850. Epub 2021 Feb 25.

Nadia R Sutton¹, Milan Seth¹, Ryan D Madder², Devraj Sukul^{1

3}, Simon R Dixon⁴, Louis A Cannon⁵, Hitinder S Gurm^{1

3}

¹ Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor (N.R.S., M.S., D.S., H.S.G.).
² Division of Cardiology, Spectrum Health, Grand Rapids, MI (R.D.M.).
³ Department of Medicine, Section of Cardiology, Veterans Affairs Medical Center, Ann Arbor, MI (D.S., H.S.G.).
⁴ Department of Cardiovascular Medicine, Beaumont Hospital, Royal Oak, MI (S.R.D.).
⁵ Cardiac and Vascular Research Center of Northern Michigan, Petoskey (L.A.C.).

Abstract

[Figure: see text].

Keywords: drug-eluting stents; mortality; percutaneous coronary intervention; safety; thrombosis.